Impact Story: Finding a Better Test for Predicting the Risk Drugs Pose to the Heart | FDA

Impact Story: Finding a Better Test for Predicting the Risk Drugs Pose to the Heart | FDA

FDA research is laying the groundwork for a new paradigm for assessing the potential of drug candidates to cause a potentially fatal cardiac arrhythmia called torsades de pointes. This paradigm, which is being developed through the CiPA initiative, has the potential to be far less costly and to result in far less attrition of drug candidates due to cardiotoxicity concerns.

To learn more, please visit: FDA CDER Impact Story.